# Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis

> **NCT01490411** · PHASE2 · COMPLETED · sponsor: **Allergopharma GmbH & Co. KG** · enrollment: 37 (actual)

## Conditions studied

- Allergic Rhinoconjunctivitis

## Interventions

- **DRUG:** Placebo
- **BIOLOGICAL:** rBet v1-FV
- **BIOLOGICAL:** rBet v1-FV
- **BIOLOGICAL:** rBet v1-FV
- **BIOLOGICAL:** rBet v1-FV

## Key facts

- **NCT ID:** NCT01490411
- **Lead sponsor:** Allergopharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-04
- **Final completion:** 2011-09
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2014-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01490411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01490411, "Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01490411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*